Edwards Lifesciences raises 2026 outlook after Q3 exceeds growth expectations
Edwards 11.2% YoY growth in Q3 was driven by sales growth in its TAVR and TMTT segments at 8% and 44%, respectively.
Edwards 11.2% YoY growth in Q3 was driven by sales growth in its TAVR and TMTT segments at 8% and 44%, respectively.
The British government will now change up AI-enabled medical device regulation to encourage innovation with the appropriate guardrails.
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Australia starts investigation into OpenAI Medicare breach
Industry partnership will determine the success of the transition to low-GWP pMDIs
UK government champions healthtech through new NHS access programme